EXO Biologics

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2025-12-31",
    "legal_form_change": false
  },
  "bedrijfsrevisor": {
    "quote": "par le reviseur d\u2019entreprises d\u00E9sign\u00E9 par le conseil d\u2019administration, \u00E0 savoir Baker Tilly Audit, Comptabilit\u00E9, Conseil SRL ayant son si\u00E8ge \u00E0 4633 Soumange, Rue de la Clef 39, num\u00E9ro d\u2019entreprise 0468.517.819 (RPM Li\u00E8ge, division Li\u00E8ge), repr\u00E9sent\u00E9e par Monsieur Christophe HABETS, reviseur d\u2019entreprises",
    "firm_kbo": "0468.517.819",
    "firm_name": "Baker Tilly Audit, Comptabilit\u00E9, Conseil SRL",
    "ibr_number": null,
    "individual_name": "Christophe HABETS"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  },
  "signature_regime": null,
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 2000000.0,
      "currency": "EUR",
      "after_eur": 7181820.14,
      "delta_eur": 2000000.0,
      "before_eur": 5181820.14,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2025-12-31",
      "evidence_quote": "augmenter le capital \u00E0 concurrence de deux millions (\u20AC 2.000.000,00) pour le porter de cinq millions cent quatre-vingt-un mille huit cent vingt euros quatorze cents (\u20AC 5.181.820,14) \u00E0 sept millions cent quatre-vingt-un mille huit cent vingt euros quatorze cents (\u20AC 7.181.820,14) par la cr\u00E9ation quatre mille six cent neuf (4.609) nouvelles Actions Classe A ... destin\u00E9es \u00E0 \u00EAtre attribu\u00E9es ... en r\u00E9mun\u00E9ration de l\u2019apport, \u00E0 concurrence de deux millions (\u20AC 2.000.000,00), d\u2019une cr\u00E9ance qu\u2019il d\u00E9tient sur la soci\u00E9t\u00E9.",
      "contribution_type": "in_kind"
    },
    {
      "kind": "capital_decrease",
      "amount": 2061102.26,
      "currency": "EUR",
      "after_eur": 5120717.88,
      "delta_eur": -2061102.26,
      "before_eur": 7181820.14,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2025-12-31",
      "evidence_quote": "r\u00E9duire le capital \u00E0 concurrence de deux millions soixante et un mille cent deux euros vingt-six cents (\u20AC 2.061.102,26) pour le ramener de sept millions cent quatre-vingt-un mille huit cent vingt euros quatorze cents (\u20AC 7.181.820,14) \u00E0 cinq millions cent vingt mille sept cent dix-sept euros quatre-vingt-huit cents (\u20AC 5.120.717,88) par apurement de la totalit\u00E9 des pertes subies au 31 d\u00E9cembre 2024 et sans r\u00E9duction du nombre d\u2019actions.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 7181820.14,
      "delta_eur": 2000000.0,
      "before_eur": 5181820.14,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "Pieter VAN ROMPAY",
          "share_class": "A",
          "liberation_pct": 100.0,
          "contribution_kind": "schuldvordering",
          "n_shares_subscribed": 4609,
          "contribution_amount_eur": 2000000.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "pair_comptable",
        "share_class": "A",
        "n_new_shares": 4609,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 433.92
      },
      "decrease_purpose": null,
      "contribution_type": "inschrijvingsrechten_uitgifte",
      "paid_up_delta_eur": 2000000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_decrease",
      "after_eur": 5120717.88,
      "delta_eur": -2061102.26,
      "before_eur": 7181820.14,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": "loss_absorption",
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_conversion",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Johan Kiebooms",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2026-01-23",
    "filing_date": "2026-01-21",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2025-12-31",
    "unanimous": null,
    "under_authorized_capital": true,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": {
    "waived": true,
    "firm_kbo": "0468.517.819",
    "firm_name": "Baker Tilly Audit, Comptabilit\u00E9, Conseil SRL",
    "ibr_number": null,
    "mission_type": "apport_nature",
    "individual_name": "Christophe HABETS"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": null,
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal du 31 d\u00E9cembre 2025",
    "procuration(s)",
    "rapports",
    "texte des statuts",
    "extrait"
  ],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 71020,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 14660,
      "class_name": "B",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 16875,
      "class_name": "C",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    }
  ]
}

{
  "notary": {
    "name": "Johan Kiebooms",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2026-01-23",
    "filing_date": "2026-01-21",
    "act_kind_objet": "CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS)"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2025-12-31",
    "unanimous": null
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "full_restatement",
      "legal_form_change",
      "wvv_adaptation",
      "object_change",
      "share_split",
      "share_consolidation",
      "share_class_creation",
      "board_authorized_capital",
      "governance_restructure",
      "liquidation_preference_introduction"
    ],
    "scope": "full_restatement",
    "trigger": "wvv_adaptation",
    "language_after": "fr",
    "language_before": "nl"
  },
  "bedrijfsrevisor": {
    "firm_kbo": "0468.517.819",
    "firm_name": "Baker Tilly Audit, Comptabilit\u00E9, Conseil SRL",
    "ibr_number": null,
    "individual_name": "Christophe HABETS"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full_after": "EXO Biologics",
    "legal_form_after": "Soci\u00E9t\u00E9 anonyme",
    "name_full_before": "EXO Biologics",
    "current_zetel_raw": "Boulevard de Patience et Beaujonc 3 bte 2 : 4000 Li\u00E8ge",
    "legal_form_before": "Soci\u00E9t\u00E9 anonyme"
  },
  "special_mandates": [],
  "articles_modified": [
    {
      "summary": "L\u0027article 5 des statuts a \u00E9t\u00E9 modifi\u00E9 pour refl\u00E9ter la nouvelle situation du capital et des actions apr\u00E8s l\u0027augmentation et la r\u00E9duction du capital.",
      "new_text": "Le capital est fix\u00E9 \u00E0 cinq millions cent vingt mille sept cent dix-sept euros quatre-vingt-huit cents (\u20AC 5.120.717,88). Il est repr\u00E9sent\u00E9 par cent deux mille cinq cent cinquante-cinq (102.555) actions, sans mention de valeur nominale, repr\u00E9sentant chacune une part \u00E9gale du capital, dont - 71.020 actions num\u00E9rot\u00E9es de 1 \u00E0 60.972, de 76.215 \u00E0 78.698, de 91.453 \u00E0 94.034, de 96.353 \u00E0 96.725 et de 97.9",
      "change_kind": "amended",
      "article_title": null,
      "article_number": "5"
    }
  ],
  "governance_change": {
    "organ_kind_after": "college",
    "organ_kind_before": "college",
    "admin_delegated_added": [],
    "representation_rule_after": "twee_gezamenlijk",
    "co_signature_threshold_eur": null,
    "representation_rule_before": "twee_gezamenlijk"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Johan Kiebooms",
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal du 31 d\u00E9cembre 2025",
    "procuration(s)",
    "rapports",
    "texte des statuts",
    "extrait"
  ],
  "shareholder_rights": null,
  "voorwerp_change_summary": "L\u0027objet de l\u0027acte inclut la traduction et la coordination des statuts, ainsi que d\u0027autres modifications, notamment li\u00E9es \u00E0 l\u0027augmentation et la r\u00E9duction du capital, la cr\u00E9ation de nouvelles actions de classe A, et la reclassification d\u0027actions existantes.",
  "capital_structure_change": {
    "operations": [
      "capital_increase_cash",
      "capital_decrease",
      "share_class_creation",
      "share_class_merge"
    ],
    "split_ratio": null,
    "shares_after": 102555,
    "shares_before": 102555,
    "capital_after_eur": 7181820.14,
    "capital_before_eur": 5181820.14,
    "share_classes_after": [
      {
        "count": 71020,
        "label": "A",
        "rights_summary": "Participent dans les r\u00E9sultats au prorata temporis.",
        "voting_per_share": 1.0
      },
      {
        "count": 14660,
        "label": "B",
        "rights_summary": "Participent dans les r\u00E9sultats au prorata temporis.",
        "voting_per_share": 1.0
      },
      {
        "count": 16875,
        "label": "C",
        "rights_summary": "Participent dans les r\u00E9sultats au prorata temporis.",
        "voting_per_share": 1.0
      }
    ]
  },
  "coordinated_text_lineage": null
}

{
  "notary": {
    "name": "Frederik Vlaminck",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2024-12-20",
    "filing_date": "2024-12-18",
    "act_kind_objet": "CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS)"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2024-12-12",
    "unanimous": null
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "targeted_amendment"
    ],
    "scope": "targeted_articles",
    "trigger": "capital_change_consequence",
    "language_after": null,
    "language_before": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full_after": "EXO Biologics",
    "legal_form_after": "Soci\u00E9t\u00E9 anonyme",
    "name_full_before": "EXO Biologics",
    "current_zetel_raw": "Boulevard de Patience et Beaujonc 3 bte 2 : 4000 Li\u00E8ge",
    "legal_form_before": "Soci\u00E9t\u00E9 anonyme"
  },
  "special_mandates": [],
  "articles_modified": [
    {
      "summary": "Adaptation of article 5 of the statutes to the new capital situation, replacing the first sentence with the new capital amount.",
      "new_text": "Le capital est fix\u00E9 \u00E0 cinq millions cent quatre-vingt-un mille huit cent vingt euros quatorze cents (\u20AC5.181.820,14).",
      "change_kind": "amended",
      "article_title": null,
      "article_number": "5"
    }
  ],
  "governance_change": null,
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal du 12 d\u00E9cembre 2024",
    "procurations",
    "texte des statuts",
    "extrait"
  ],
  "shareholder_rights": null,
  "voorwerp_change_summary": null,
  "capital_structure_change": {
    "operations": [
      "capital_decrease"
    ],
    "split_ratio": null,
    "shares_after": null,
    "shares_before": null,
    "capital_after_eur": 5181820.14,
    "capital_before_eur": 10314687.9,
    "share_classes_after": []
  },
  "coordinated_text_lineage": null
}

{
  "notary": {
    "name": "Frederik Vlaminck",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2024-12-20",
    "filing_date": "2024-12-18",
    "act_kind_objet": "CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS)"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "date": "2024-12-12",
    "unanimous": null
  },
  "agm_change": {
    "new_schedule": null,
    "old_schedule": null,
    "effective_from_year": null,
    "rule_changes_summary": "Adaptation of article 5 of the statutes to the new capital situation, replacing the first sentence with a new clause defining the capital."
  },
  "detected_kind": "agm_rules_change",
  "other_address": null,
  "mandate_renewal": null,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "SA"
  },
  "accounts_deposit": {
    "filing_kind": null,
    "fiscal_year_end": "2023-12-31",
    "filing_reference": "*24453545*"
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal du 12 d\u00E9cembre 2024",
    "procurations",
    "texte des statuts",
    "extrait"
  ],
  "fiscal_year_change": null,
  "liquidation_closure": null,
  "officer_designation": null,
  "special_procuration": null,
  "is_volet_a_only_stub": false,
  "vakbekwaamheid_change": null,
  "should_reroute_to_category": null,
  "single_shareholder_declaration": null
}

{
  "events": [
    {
      "kind": "capital_decrease",
      "after_eur": 5181820.14,
      "delta_eur": -5132867.76,
      "before_eur": 10314687.9,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": "loss_absorption",
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
    }
  ],
  "notary": {
    "name": "Frederik Vlaminck",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2024-12-20",
    "filing_date": "2024-12-18",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2024-12-12",
    "unanimous": null,
    "under_authorized_capital": true,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal du 12 d\u00E9cembre 2024",
    "procurations",
    "texte des statuts",
    "extrait"
  ],
  "shareholders_after": [],
  "share_classes_after": []
}

{
  "notary": {
    "name": "Frederik Vlaeminck",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2024-09-13",
    "filing_date": "2024-09-11",
    "act_kind_objet": "CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS)"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2024-09-03",
    "unanimous": null
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "full_restatement",
      "capital_change_consequence"
    ],
    "scope": "full_restatement",
    "trigger": "capital_change_consequence",
    "language_after": null,
    "language_before": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full_after": "EXO Biologics",
    "legal_form_after": "Soci\u00E9t\u00E9 anonyme",
    "name_full_before": "EXO Biologics",
    "current_zetel_raw": "Boulevard de Patience et Beaujonc 3 bte 2 : 4000 Li\u00E8ge",
    "legal_form_before": "Soci\u00E9t\u00E9 anonyme"
  },
  "special_mandates": [],
  "articles_modified": [
    {
      "summary": "Adaptation du texte de l\u0027article 5 des statuts \u00E0 la nouvelle situation du capital et du nombre d\u0027actions, avec remplacement du texte.",
      "new_text": "Le capital est fix\u00E9 \u00E0 dix millions trois cent quatorze mille six cent quatre-vingt-sept euros nonante cents (\u20AC 10.314.687,90). Il est repr\u00E9sent\u00E9 par nonante-sept mille neuf cent quarante-six (97.946) actions, sans mention de valeur nominale, repr\u00E9sentant chacune une part \u00E9gale du capital, dont - 66.749 actions num\u00E9rot\u00E9es de 1 \u00E0 60.972, de 76.215 \u00E0 79.036, de 91.453 \u00E0 94.034 et de 96.353 \u00E0 96.725 a",
      "change_kind": "amended",
      "article_title": null,
      "article_number": "5"
    }
  ],
  "governance_change": null,
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Frederik Vlaeminck",
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal du 3 septembre 2024",
    "procurations",
    "texte des statuts",
    "extrait"
  ],
  "shareholder_rights": null,
  "voorwerp_change_summary": null,
  "capital_structure_change": {
    "operations": [
      "capital_increase_cash",
      "share_class_creation"
    ],
    "split_ratio": null,
    "shares_after": 97946,
    "shares_before": 9623021,
    "capital_after_eur": 10314687.9,
    "capital_before_eur": 9623021.9,
    "share_classes_after": [
      {
        "count": 373,
        "label": "A",
        "rights_summary": "M\u00EAmes droits et avantages que les actions existantes de leur classe; participation aux r\u00E9sultats au pro rata temporis; souscrites en esp\u00E8ces au prix moyen arrondi de 433,92 \u20AC par action; imm\u00E9diatement lib\u00E9r\u00E9es enti\u00E8rement.",
        "voting_per_share": null
      },
      {
        "count": 1221,
        "label": "B",
        "rights_summary": "M\u00EAmes droits et avantages que les actions existantes de leur classe; participation aux r\u00E9sultats au pro rata temporis; souscrites en esp\u00E8ces au prix moyen arrondi de 433,92 \u20AC par action; imm\u00E9diatement lib\u00E9r\u00E9es enti\u00E8rement.",
        "voting_per_share": null
      },
      {
        "count": 1594,
        "label": "C",
        "rights_summary": "M\u00EAmes droits et avantages que les actions existantes de leur classe; participation aux r\u00E9sultats au pro rata temporis; souscrites en esp\u00E8ces au prix moyen arrondi de 433,92 \u20AC par action; imm\u00E9diatement lib\u00E9r\u00E9es enti\u00E8rement.",
        "voting_per_share": null
      }
    ]
  },
  "coordinated_text_lineage": null
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 10314687.9,
      "delta_eur": 691666.0,
      "before_eur": 9623021.9,
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 1594,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 433.92
      },
      "decrease_purpose": null,
      "contribution_type": "numeraire",
      "paid_up_delta_eur": 691666.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Frederik Vlaeminck",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-09-13",
    "filing_date": "2024-09-11",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2024-09-03",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal du 3 septembre 2024",
    "procurations",
    "texte des statuts",
    "extrait"
  ],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 66749,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": null
    },
    {
      "n_shares": 14660,
      "class_name": "B",
      "capital_share_eur": null,
      "voting_rights_per_share": null
    },
    {
      "n_shares": 16537,
      "class_name": "C",
      "capital_share_eur": null,
      "voting_rights_per_share": null
    }
  ]
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2024-09-03",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  },
  "signature_regime": null,
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 691666.0,
      "currency": "EUR",
      "after_eur": 10314687.9,
      "delta_eur": 691666.0,
      "before_eur": 9623021.9,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2024-09-03",
      "evidence_quote": "augmenter le capital de la soci\u00E9t\u00E9 \u00E0 concurrence de six cent nonante-et-un mille six cent soixante-six euros (\u20AC 691.666,00) pour le porter de neuf millions six cent vingt-trois mille vingt et un euros nonante cents (\u20AC 9.623.021,90) \u00E0 dix millions trois cent quatorze mille six cent quatre-vingt-sept euros nonante cents (\u20AC 10.314.687,90) par apport en num\u00E9raire",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Amel TOUNSI",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "NOSHAQ PARTNERS",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-02-07",
      "evidence_quote": "Par un courrier du 6 f\u00E9vrier 2024 adress\u00E9 au Conseil d\u0027administration de la S.A. EXO BIOLOGICS, la S.R.L. NOSHAQ PARTNERS a inform\u00E9 la soci\u00E9t\u00E9 du remplacement de son repr\u00E9sentant permanent, Madame Amel TOUNSI, par Monsieur Eric BRANDT, avec effet au 7 f\u00E9vrier 2024"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Eric BRANDT",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "NOSHAQ PARTNERS",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-02-07",
      "evidence_quote": "Par un courrier du 6 f\u00E9vrier 2024 adress\u00E9 au Conseil d\u0027administration de la S.A. EXO BIOLOGICS, la S.R.L. NOSHAQ PARTNERS a inform\u00E9 la soci\u00E9t\u00E9 du remplacement de son repr\u00E9sentant permanent, Madame Amel TOUNSI, par Monsieur Eric BRANDT, avec effet au 7 f\u00E9vrier 2024"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "rep_rotation",
      "role": "vaste_vertegenwoordiger",
      "person": {
        "rrn": null,
        "name": "Eric BRANDT",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": "rectification",
      "via_org": {
        "kbo": null,
        "name": "NOSHAQ PARTNERS",
        "address": null,
        "country": null,
        "legal_form": "S.R.L."
      },
      "statutory": null,
      "compensated": null,
      "effective_date": "2024-02-07",
      "evidence_quote": "Par un courrier du 6 f\u00E9vrier 2024 adress\u00E9 au Conseil d\u0027administration de la S.A. EXO BIOLOGICS, la S.R.L. NOSHAQ PARTNERS a inform\u00E9 la soci\u00E9t\u00E9 du remplacement de son repr\u00E9sentant permanent, Madame Amel TOUNSI, par Monsieur Eric BRANDT, avec effet au 7 f\u00E9vrier 2024",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": "Eric BRANDT",
      "rep_rotation_old_rep": "Amel TOUNSI",
      "effective_date_qualifier": null
    },
    {
      "kind": "decharge_granted",
      "role": null,
      "person": null,
      "reason": null,
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "",
      "decharge_status": "granted",
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    }
  ],
  "notary": {
    "name": null,
    "firm_city": null,
    "firm_name": null,
    "office_city": "LIEGE",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": null,
    "filing_date": null,
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decisions": [
    {
      "body": "enig_aandeelhouder_schriftelijk",
      "date": "2024-06-09",
      "unanimous": null
    }
  ],
  "is_correction": true,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "S.A."
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "NOSHAQ",
    "person_name": null,
    "org_rep_person_name": "St\u00E9phanie CRAHAY",
    "person_role_at_subject": null
  },
  "co_filed_documents": [],
  "corrected_publication_numac": "24093411"
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Amel TOUNSI",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0732982379",
        "name": "NOSHAQ IMMO",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-02-07",
      "evidence_quote": "la S.R.L. NOSHAQ PARTNERS a inform\u00E9 la soci\u00E9t\u00E9 du remplacement de son repr\u00E9sentant permanent, Madame Amel TOUNSI, par Monsieur Yvan ABSIL, avec effet au 7 f\u00E9vrier 2024"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Yvan ABSIL",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0732982379",
        "name": "NOSHAQ IMMO",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-02-07",
      "evidence_quote": "la S.R.L. NOSHAQ PARTNERS a inform\u00E9 la soci\u00E9t\u00E9 du remplacement de son repr\u00E9sentant permanent, Madame Amel TOUNSI, par Monsieur Yvan ABSIL, avec effet au 7 f\u00E9vrier 2024"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 2627152.0,
      "currency": "EUR",
      "after_eur": 7248021.9,
      "delta_eur": 2627152.0,
      "before_eur": 4620869.9,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2023-12-29",
      "evidence_quote": "d\u2019augmenter le capital \u00E0 concurrence de deux millions six cent vingt-sept mille cent cinquante-deux euros (\u20AC 2.627.152,00) pour le porter de quatre millions six cent vingt mille huit cent soixante-neuf euros nonante cents (\u20AC 4.620.869,90) \u00E0 sept millions deux cent quarante-huit mille vingt et un euros nonante cents (\u20AC 7.248.021,90) par la cr\u00E9ation de six mille cent septante-et-un (6.171) nouvelles Actions Classe C... destin\u00E9es \u00E0 \u00EAtre attribu\u00E9es, en tant qu\u2019actions enti\u00E8rement lib\u00E9r\u00E9es, en r\u00E9mun\u00E9ration de l\u2019apport des cr\u00E9ances d\u00E9tenues par les souscripteurs \u00E0 l\u2019\u00E9gard de la soci\u00E9t\u00E9 \u00E0 concurrence de deux millions six cent vingt-sept mille cent cinquante-deux euros (\u20AC 2.627.152,00) au total",
      "contribution_type": "in_kind"
    },
    {
      "kind": "capital_increase",
      "amount": 2375000.0,
      "currency": "EUR",
      "after_eur": 9623021.9,
      "delta_eur": 2375000.0,
      "before_eur": 7248021.9,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2023-12-29",
      "evidence_quote": "d\u2019augmenter le capital de la soci\u00E9t\u00E9 \u00E0 concurrence de deux millions trois cent septante-cinq mille euros (\u20AC 2.375.000,00) pour le porter de sept millions deux cent quarante-huit mille vingt et un euros nonante cents (\u20AC 7.248.021,90) \u00E0 neuf millions six cent vingt-trois mille vingt et un euros nonante cents (\u20AC 9.623.021,90) par apport en num\u00E9raire et par la cr\u00E9ation de cinq mille cinq cents (5.500) actions... qui seront imm\u00E9diatement lib\u00E9r\u00E9es enti\u00E8rement",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 7248021.9,
      "delta_eur": 2627152.0,
      "before_eur": 4620869.9,
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": "C",
        "n_new_shares": 6171,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "inschrijvingsrechten_uitgifte",
      "paid_up_delta_eur": 2627152.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_increase",
      "after_eur": 9623021.9,
      "delta_eur": 2375000.0,
      "before_eur": 7248021.9,
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 5500,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "geld",
      "paid_up_delta_eur": 2375000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": 5500,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "warrant_issuance",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_increase",
      "after_eur": 9623022.0,
      "delta_eur": 0.1,
      "before_eur": 9623021.9,
      "_arith_derived": "delta",
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "inschrijvingsrechten_uitgifte",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Johan KIEBOOMS",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-02-16",
    "filing_date": "2024-02-14",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2023-12-29",
    "unanimous": null,
    "under_authorized_capital": true,
    "underlying_resolution_date": "2023-12-29"
  },
  "bedrijfsrevisor": {
    "waived": false,
    "firm_kbo": "0641.763.381",
    "firm_name": "REWISE AD REVISEUR D\u0027ENTREPRISES",
    "ibr_number": null,
    "mission_type": "apport_nature",
    "individual_name": "Axel DUMONT"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "Exp\u00E9dition du proc\u00E8s-verbal du 29 d\u00E9cembre 2023",
    "texte des statuts",
    "procurations",
    "extrait"
  ],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 66376,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 14660,
      "class_name": "B",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    },
    {
      "n_shares": 15316,
      "class_name": "C",
      "capital_share_eur": null,
      "voting_rights_per_share": 1.0
    }
  ]
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 5600000.0,
      "delta_eur": 5000000.0,
      "before_eur": 600000.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 16214,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 308.33
      },
      "decrease_purpose": null,
      "contribution_type": "inschrijvingsrechten_uitgifte",
      "paid_up_delta_eur": 5000000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_increase",
      "after_eur": 8600000.0,
      "delta_eur": 3000000.0,
      "before_eur": 5600000.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 8467,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 354.27
      },
      "decrease_purpose": null,
      "contribution_type": "inschrijvingsrechten_uitgifte",
      "paid_up_delta_eur": 3000000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_decrease",
      "after_eur": 4620869.9,
      "delta_eur": -3979130.1,
      "before_eur": 8600000.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": "loss_absorption",
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Frederik Vlaminck",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2023-10-12",
    "filing_date": "2023-10-10",
    "act_kind_objet": "Objet de l\u0027acte : CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), DEMISSIONS, NOMINATIONS"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2023-09-11",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": {
    "waived": false,
    "firm_kbo": "0419.122.548",
    "firm_name": "KPMG R\u00E9viseurs d\u0027Entreprises",
    "ibr_number": null,
    "mission_type": "apport_nature",
    "individual_name": "Olivier DE CLERCQ"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "exp\u00E9dition du proc\u00E8s-verbal du 11 septembre 2023",
    "procurations",
    "texte des statuts",
    "extrait"
  ],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 63794,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": null
    },
    {
      "n_shares": 12342,
      "class_name": "B",
      "capital_share_eur": null,
      "voting_rights_per_share": null
    },
    {
      "n_shares": 8545,
      "class_name": "C",
      "capital_share_eur": null,
      "voting_rights_per_share": null
    }
  ]
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 5000000,
      "currency": "EUR",
      "after_eur": 5600000,
      "delta_eur": 5000000,
      "before_eur": 600000,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2023-09-11",
      "evidence_quote": "d\u2019augmenter le capital \u00E0 concurrence de cinq millions (\u20AC 5.000.000,00) pour le porter de six cent mille (\u20AC 600.000,00) \u00E0 cinq millions six cent mille euros (\u20AC 5.600.000,00) par la cr\u00E9ation de seize mille deux cent quatorze (16.214) nouvelles actions ... destin\u00E9es \u00E0 \u00EAtre attribu\u00E9es, en tant qu\u2019actions enti\u00E8rement lib\u00E9r\u00E9es, en r\u00E9mun\u00E9ration de l\u2019apport des cr\u00E9ances d\u00E9tenues par les souscripteurs \u00E0 l\u2019encontre de la soci\u00E9t\u00E9 \u00E0 concurrence de cinq millions (\u20AC 5.000.000,00) en total",
      "contribution_type": "in_kind"
    },
    {
      "kind": "capital_increase",
      "amount": 3000000,
      "currency": "EUR",
      "after_eur": 8600000,
      "delta_eur": 3000000,
      "before_eur": 5600000,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2023-09-11",
      "evidence_quote": "d\u2019augmenter le capital \u00E0 concurrence de trois millions (\u20AC 3.000.000,00) pour le porter de cinq millions six cent mille euros (\u20AC 5.600.000,00) \u00E0 huit millions six cent mille euros (\u20AC 8.600.000,00) par la cr\u00E9ation de huit mille quatre cent soixante-sept (8.467) nouvelles actions ... destin\u00E9es \u00E0 \u00EAtre attribu\u00E9es, en tant qu\u2019actions enti\u00E8rement lib\u00E9r\u00E9es, en r\u00E9mun\u00E9ration de l\u2019apport des cr\u00E9ances d\u00E9tenues par les souscripteurs \u00E0 l\u2019encontre de la soci\u00E9t\u00E9 \u00E0 concurrence de trois millions (\u20AC 3.000.000,00) en total",
      "contribution_type": "in_kind"
    },
    {
      "kind": "capital_decrease",
      "amount": 3979130.1,
      "currency": "EUR",
      "after_eur": 4620869.9,
      "delta_eur": -3979130.1,
      "before_eur": 8600000,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2023-09-11",
      "evidence_quote": "de r\u00E9duire le capital \u00E0 concurrence de trois millions neuf cent septante-neuf mille cent trente euros dix cents (\u20AC 3.979.130,10) pour le ramener de huit millions six cent mille euros (\u20AC 8.600.000,00) \u00E0 quatre millions six cent vingt mille huit cent soixante-neuf euros nonante cents (\u20AC 4.620.869,90) par apurement de la totalit\u00E9 des pertes subies au 31 d\u00E9cembre 2022",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "substantive_delegation",
      "role": "d\u00E9l\u00E9gu\u00E9",
      "person": {
        "rrn": null,
        "name": "Hugues Wallemacq",
        "address": "4458 Fexhe-Slins, 31 Rue Neuve",
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "Nommer la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u003CBiotech Management \u0026 Consulting \u003E, avec adresse \u00E0 4458 Fexhe-Slins, Rue Neuve 31, num\u00E9ro d\u0027entreprise 0741.644.479 (RPM Li\u00E8ge, division Li\u00E8ge), comme d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re, qui sera repr\u00E9sent\u00E9e de fa\u00E7on permanente par Monsieur Hugues Wallemacq",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "substantive_delegation",
      "role": "d\u00E9l\u00E9gu\u00E9",
      "person": null,
      "reason": null,
      "subkind": null,
      "via_org": {
        "kbo": "0741.644.479",
        "name": "Biotech Management \u0026 Consulting SRL",
        "address": "4458 Fexhe-Slins, Rue Neuve 31",
        "country": "BE",
        "legal_form": "SRL"
      },
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "Nommer la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u003CBiotech Management \u0026 Consulting \u003E, avec adresse \u00E0 4458 Fexhe-Slins, Rue Neuve 31, num\u00E9ro d\u0027entreprise 0741.644.479 (RPM Li\u00E8ge, division Li\u00E8ge), comme d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "substantive_delegation",
      "role": "d\u00E9l\u00E9gu\u00E9",
      "person": null,
      "reason": null,
      "subkind": null,
      "via_org": {
        "kbo": "0741.644.479",
        "name": "Biotech Management \u0026 Consulting SRL",
        "address": "4458 Fexhe-Slins, Rue Neuve 31",
        "country": "BE",
        "legal_form": "SRL"
      },
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "mandater la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u003C\u003CBiotech Management \u0026 Consulting \u003E, de repr\u00E9senter la Soci\u00E9t\u00E9 \u00E0 l\u0027\u00E9gard des tiers en justice et ailleurs en ce qui concerne",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "decharge_granted",
      "role": "administrateur",
      "person": null,
      "reason": null,
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "procuration \u00E0 chaque administrateur de la Soci\u00E9t\u00E9",
      "decharge_status": "granted",
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "decharge_granted",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Robin Van Gysel",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "procuration \u00E0 chaque administrateur de la Soci\u00E9t\u00E9, ainsi qu\u0027au monsieur Robin Van Gysel",
      "decharge_status": "granted",
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "decharge_granted",
      "role": "administrateur",
      "person": null,
      "reason": null,
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "procuration \u00E0 chaque administrateur de la Soci\u00E9t\u00E9",
      "decharge_status": "granted",
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "decharge_granted",
      "role": null,
      "person": null,
      "reason": null,
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "le mandataire peut faire, au nom de la Soci\u00E9t\u00E9, toutes des d\u00E9clarations et signer tous les documents et formulaires",
      "decharge_status": "granted",
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "decharge_granted",
      "role": null,
      "person": null,
      "reason": null,
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "le mandataire peut faire, au nom de la Soci\u00E9t\u00E9, toutes des d\u00E9clarations et signer tous les documents et formulaires",
      "decharge_status": "granted",
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    }
  ],
  "notary": {
    "name": null,
    "firm_city": null,
    "firm_name": null,
    "office_city": null,
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": null,
    "filing_date": "2022-12-04",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decisions": [
    {
      "body": "conseil_d_administration",
      "date": "2022-11-15",
      "unanimous": true
    }
  ],
  "is_correction": false,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "Soci\u00E9t\u00E9 anonyme"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Robin Van Gysel",
    "org_rep_person_name": null,
    "person_role_at_subject": "Mandataire sp\u00E9cial"
  },
  "co_filed_documents": [
    "Proc\u00E8s-verbal du 15 novembre 2022"
  ],
  "corrected_publication_numac": null
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "siege_social",
      "new_address": {
        "raw": "4000 Li\u00E8ge, Boulevard Patience et Beaujonc, 3-Bo\u00EEte 2",
        "city": "Li\u00E8ge",
        "region": "waals_gewest",
        "street": "Boulevard Patience et Beaujonc",
        "country": "BE",
        "postcode": "4000",
        "box_number": "2",
        "street_number": "3",
        "locality_suffix": null
      },
      "old_address": null,
      "effective_date": null,
      "evidence_quote": "Apr\u00E8s d\u00E9lib\u00E9ration, le Conseil d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de transf\u00E9rer l\u0027adresse du si\u00E8ge social de la Soci\u00E9t\u00E9 vers 4000 Li\u00E8ge, Boulevard Patience et Beaujonc, 3-Bo\u00EEte 2.",
      "region_changed": false,
      "is_statute_change": true,
      "nationality_change": false,
      "old_address_source": "inferred",
      "statute_clause_text": null,
      "statute_article_number": null,
      "effective_date_qualifier": null,
      "statutaire_vs_werkelijke": null,
      "linguistic_region_changed": false,
      "court_jurisdiction_changed": false,
      "effective_date_is_approximate": null
    }
  ],
  "notary": {
    "name": null,
    "firm_city": null,
    "firm_name": null,
    "office_city": null,
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": null,
    "filing_date": "2022-12-04",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "conseil_d_administration",
    "date": "2022-11-15",
    "unanimous": true
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "_kbo_filled_from_list": true
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Robin Van Gysel",
    "org_rep_person_name": null,
    "person_role_at_subject": "Mandataire sp\u00E9cial"
  },
  "co_filed_documents": [
    "Proc\u00E8s-verbal du 15 novembre 2022"
  ]
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "statutaire",
      "new_address": {
        "city": "Li\u00E8ge",
        "region": "Brussels Gewest",
        "street": "Boulevard Patience et Beaujonc",
        "country": "BE",
        "postcode": "4000",
        "box_number": "2",
        "street_number": "3"
      },
      "old_address": {
        "city": "Li\u00E8ge",
        "region": "Brussels Gewest",
        "street": "Boulevard Gustave-Kleyer",
        "country": "BE",
        "postcode": "4000",
        "box_number": null,
        "street_number": "17"
      },
      "effective_date": "2022-11-15",
      "evidence_quote": "1.Transfert du si\u00E8ge social\nApr\u00E8s d\u00E9lib\u00E9ration, le Conseil d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de transf\u00E9rer l\u0027adresse du si\u00E8ge social de la Soci\u00E9t\u00E9\nvers 4000 Li\u00E8ge, Boulevard Patience et Beaujonc, 3-Bo\u00EEte 2."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "dagelijks_bestuur",
      "person": {
        "rrn": null,
        "name": "Hugues Wallemacq",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0741644479",
        "name": "Biotech Management \u0026 Consulting SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "Apr\u00E8s d\u00E9lib\u00E9ration, le Conseil d\u00E9cide \u00E0 l\u0027unanimit\u00E9 (i) de nommer la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u003C Biotech Management \u0026 Consulting \u003E, avec adresse \u00E0 4458 Fexhe-Slins, Rue Neuve 31, num\u00E9ro d\u0027entreprise 0741.644.479 (RPM Li\u00E8ge, division Li\u00E8ge), comme d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re, qui sera rep"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "JURGA Marcin",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2021-09-29",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de nominer les personnes suivantes comme administrateur de la Soci\u00E9t\u00E9 jusque la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de l\u0027ann\u00E9e 2026: -Monsieur JURGA Marcin, habitant \u00E0 2840 Rumst, Kloosterstraat 28;"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "TOUNSI Amel",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0426624509",
        "name": "NOSHAQ",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2021-09-29",
      "evidence_quote": "la soci\u00E9t\u00E9 anonyme NOSHAQ, ayant son si\u00E8ge \u00E0 4000 Li\u00E8ge, Rue Lambert-Lombard 3, num\u00E9ro d\u0027entreprise 0426.624.509 (RPM Li\u00E8ge, division Li\u00E8ge), qui a d\u00E9clar\u00E9 de nommer en qualit\u00E9 de repr\u00E9sentant permanent, Madame TOUNSI Amel, habitant \u00E0 1090 Jette, Jean Gabinplein 1 A1;"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "DALTON Colin Clive",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "Margarite Limited",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2021-09-29",
      "evidence_quote": "la soci\u00E9t\u00E9 \u00E9trang\u00E8re Margarite Limited, ayant son si\u00E8ge \u00E0 Quorn, Leicestershire, LE12 8DX (Royaume-Uni), 78 Loughborough Road, qui sera repr\u00E9sent\u00E9e de fa\u00E7on permanente par Monsieur DALTON Colin Clive, habitant \u00E0 Ketteringham, WYMONDHAM, Norfolk, NR18 9RU (Royaume-Uni), The Lodge, High Street."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO BIOLOGICS",
    "legal_form": "SA"
  }
}

{
  "kind": "oprichting",
  "seat": "Boulevard Gustave-Kleyer 17, 4000 Li\u00E8ge",
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "founders": [
    {
      "org": null,
      "kind": "natural_person",
      "person": {
        "dob": null,
        "name": "VAN ROMPAY Pieter",
        "niss": null,
        "address": "Lindenlaan 3, 2580 Putte"
      },
      "share_class": "nominative",
      "partner_role": null,
      "holder_org_kbo": null,
      "holder_org_name": null,
      "contribution_type": "cash",
      "amount_paid_in_eur": 200000,
      "holder_person_name": "VAN ROMPAY Pieter",
      "is_subscriber_only": false,
      "n_shares_subscribed": 20000,
      "amount_subscribed_eur": 200000,
      "is_anonymous_silent_partner": false
    },
    {
      "org": null,
      "kind": "natural_person",
      "person": {
        "dob": null,
        "name": "VAN ROMPAY Stijn",
        "niss": null,
        "address": "Vlieghavenlaan 24, 3140 Keerbergen"
      },
      "share_class": "nominative",
      "partner_role": null,
      "holder_org_kbo": null,
      "holder_org_name": null,
      "contribution_type": "cash",
      "amount_paid_in_eur": 200000,
      "holder_person_name": "VAN ROMPAY Stijn",
      "is_subscriber_only": false,
      "n_shares_subscribed": 20000,
      "amount_subscribed_eur": 200000,
      "is_anonymous_silent_partner": false
    },
    {
      "org": null,
      "kind": "natural_person",
      "person": {
        "dob": null,
        "name": "FOIDART Jean Michel Francine Charles Simonne Ren\u00E9",
        "niss": null,
        "address": "4870 Trooz, Rue Sur la Heid 3"
      },
      "share_class": "nominative",
      "partner_role": null,
      "holder_org_kbo": null,
      "holder_org_name": null,
      "contribution_type": "cash",
      "amount_paid_in_eur": 200000,
      "holder_person_name": "FOIDART Jean Michel Francine Charles Simonne Ren\u00E9",
      "is_subscriber_only": false,
      "n_shares_subscribed": 20000,
      "amount_subscribed_eur": 200000,
      "is_anonymous_silent_partner": false
    }
  ],
  "capital_eur": 600000,
  "subject_company": {
    "kbo": "0732.982.379",
    "name_full": "EXO Biologics",
    "legal_form": "SNC"
  },
  "initial_directors": [],
  "incorporation_date": "2019-08-28",
  "post_incorporation_mandates": []
}